Upon joining the study, the patient will be informed about the trial’s purpose, which is to evaluate the long-term safety and effectiveness of ozanimod for treating moderately to severely active Crohn’s disease.

The patient will be required to provide written consent to participate in the study.

The patient will receive ozanimod in the form of a hard capsule, taken orally.

The dosage and frequency of administration will be determined by the study protocol and communicated to the patient by the study team.

Throughout the study, the patient will undergo regular assessments to monitor the effectiveness and safety of the treatment.

These assessments may include measuring the Crohn’s Disease Activity Index (CDAI) score, which evaluates the severity of symptoms, and the Simple Endoscopic Score for Crohn’s Disease (SES-CD), which assesses the condition of the intestinal lining.

The patient will attend scheduled follow-up visits to track progress and any changes in symptoms.

During these visits, the study team will collect data on the patient’s response to the treatment and any side effects experienced.

Upon completion of the study, the patient will have a final assessment to evaluate the overall impact of the treatment.

The study is estimated to conclude by March 24, 2031, at which point the patient will be informed of the study’s findings and any further recommendations.